Aardvark Therapeutics AARD
NASDAQ AARD
$1.38 +0.03 (+2.22%)
As of: Nov 10, 2026 · 2:14 PM EST

Aardvark Therapeutics (AARD) EBITDA (2024 - 2026)

Updated

Aardvark Therapeutics (AARD) recorded EBITDA of -$15.07 million in Q2 2026, compared with -$15.84 million a year earlier.

Analysis

Aardvark Therapeutics (AARD) EBITDA (2024 - 2026) Analysis & Trends

On a TTM basis, Aardvark Therapeutics' EBITDA came in at -$73.91 million as of Jun 30, 2026; for FY2025, it came in at -$62.69 million.

  • Across earlier years, EBITDA came in at -$22.77 million in FY2024.
  • The Q2 2026 figure is the highest quarterly EBITDA since Q1 2025.
  • Per Business Quant, the preceding three quarters came in at -$22.45 million (Q1 2026), -$18.69 million (Q4 2025) and -$17.69 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 13.33 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 8.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 8.16 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 7.37 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 4.83 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 4.20 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 7.05 Bn
10 Aardvark Therapeutics 30.58 Mn -43.32 Mn - -15.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.07 Mn
Mar 31, 2026 -22.45 Mn
Dec 31, 2025 -18.69 Mn
Sep 30, 2025 -17.69 Mn
Jun 30, 2025 -15.84 Mn
Mar 31, 2025 -10.47 Mn
Dec 31, 2024 -9.44 Mn
Sep 30, 2024 -5.08 Mn
Jun 30, 2024 -6.08 Mn
Mar 31, 2024 -2.17 Mn
API Access

Aardvark Therapeutics EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=AARD&period=max&api_key=YOUR_API_KEY